Aclarion Inc. (Nasdaq: ACON, ACONW), a health care technology company based in Broomfield, has established a commercial agreement with the Spine Institute of Louisiana (SIL) in Shreveport, La., expanding access to its Nociscan solution. This collaboration allows SIL, a center known for its innovative treatment of chronic low back pain, to use Nociscan as part
Aclarion Inc. (Nasdaq: ACON, ACONW) has published a peer-reviewed article in Clinicoeconomics and Outcomes Research, titled “The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.” The independent cost-effectiveness analysis concludes that Nociscan is effective and less costly compared to provocative discography. The findings
Terumo Blood and Cell Technologies (Terumo BCT) named Patrick Daly as its chief business officer. This addition comes as the Lakewood company aims to expand its capabilities in response to evolving market segments. Daly brings over 30 years of experience in the business and health care sectors, having worked both domestically and internationally. He most
Aclarion Inc. (Nasdaq: ACON, ACONW) reported that its Nociscan product is now available at the Medical Imaging Center of Southern California (MICSC) in Santa Monica. Previously, MICSC offered Nociscan exclusively at its Beverly Hills location. “We are pleased to expand access to Nociscan in our Santa Monica location,” said Dr. Bradley Jabour, founder of MICSC.
Aclarion Inc. (Nasdaq: ACON, ACONW), the Broomfield healthcare technology company focused on chronic low back pain, announced an update on its improved positioning following successful strategic initiatives in the first quarter of 2025. The company raised over $20 million in Q1, maintaining nearly $15 million in cash on hand. Aclarion reported a clean capital structure,
Aclarion Inc. (NASDAQ: ACON, ACONW) announced a 1-for-27 reverse stock split of its common stock, effective before market open on March 28. On Sept. 23, 2024, the Broomfield-based company’s stockholders approved an amendment to the company’s Certificate of Incorporation to authorize a reverse stock split with the ratio set by its Board of Directors. The
Terumo Blood and Cell Technologies (Terumo BCT) has signed a memorandum of understanding (MOU) with the Osong Medical Innovation Foundation (KBIOHealth) to jointly develop workforce training for cell and gene therapy (CGT) manufacturing. The partnership aims to create training programs focused on mesenchymal stem cell (MSC) and chimeric antigen (CAR) T-cell therapies, utilizing Terumo BCT’s
Aclarion Inc. (Nasdaq: ACON, ACONW), the healthcare technology company based in Broomfield, plans expand Nociscan access across key markets in New York and New Jersey. This expansion builds on previously established Nociscan sites with RadNet affiliates in both states and is driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities
Aclarion Inc. has established a commercial agreement with Scripps Health in San Diego, Calif., expanding access to its Nociscan technology for spine physicians and more than 3.2 million residents in the greater San Diego area. The Nociscan technology utilizes MR Spectroscopy (MRS) and Augmented Intelligence to identify sources of chronic low back pain. Scripps Health
Terumo Blood and Cell Technologies (Terumo BCT) has partnered with the nonprofit National Alliance of Sickle Cell Centers (NASCC), which is focused on improving the lives of individuals with sickle cell disease (SCD). The collaboration, titled BET on Blood for SCD, aims to enhance access to blood transfusion therapy and educate healthcare providers on its
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield healthcare technology company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent. This new patent expands Aclarion’s proprietary rights to utilize magnetic resonance spectroscopy (MRS) to measure propionic acid (PA) as a biomarker for identifying potential
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology company, has named Northwestern Medicine as the initial site for its CLARITY trial. This study is aimed at demonstrating the clinical and economic value of Nociscan in spine surgery, particularly for chronic low back pain. The CLARITY trial is a randomized study designed to show